CE Courses

 

 

Companies that enroll in the 2017 CE Program will receive the following courses:

 

Melanoma 2017
This updates our 2010 Melanoma course. A great deal has changed that directly impacts risk assessment in 7 years. This course will cover every major development relevant to insurability, many of which are not even mentioned in medical manuals and left off so-called “calculators.” Melanoma has been our #1 specialty since 1986 and insurers should gain more than enough mortality advantage from this one course to pay for the whole program!

 

Insurability Frontiers
Underwriters see many cases of acute/chronic unipolar major and minor depression, and bipolar spectrum disorders. Using the most recent studies, we will delineate depression/bipolar subtypes, and the insurability impact of symptoms, comorbidities, treatment methods, complications and mortality/morbidity.

 

Case Clinic: Underwriting with Drilldowns but no APS
We have done many conventional case clinics in our program. This one is definitely not conventional! We will review a batch of cases wherein we must make an underwriting decision based on a teleinterview drilldown interview on a wide range of case scenarios including psychiatric and cardiac disorders, syncope and other symptoms, etc. Cases will be presented for participants to review and our analyses will be included for participants to match to their own assessments. The goal is to make underwriters more comfortable taking action without ordering unnecessary medical records. 

 

“Red” Drugs and Risk Triage
“Red” drugs have by definition the greatest insurability implications. However, there are aspects of “red” drug assessment that underwriters must understand to make the best decisions. This includes accurately distinguishing when a drug is “red” on a contextual basis. 25% of prescriptions are written off-label for uses not officially approved. Many such uses are widespread and easily misleading. We will cover all of major classes of “red” drugs, thereby enabling underwriters to know when medical records are needed, as well as when “red” is really “yellow” or even “green!” 

 

Myelodysplastic Syndrome and the Chronic Leukemias 
MDS is the most common life-threatening neoplastic blood disorder at older ages and the majority of cases are diagnosed incidentally based on unexpected CBC findings. Mortality is improving steadily in some subsets of chronic leukemias, enabling us to make competitive offers. We will cover all salient aspects of these 2 subjects in this course.

 

Calcium Scores and Cardiovascular Calcifications
Coronary artery calcium (CAC) scoring with multidetector CT scans is now a widely used marker for undiagnosed atherosclerotic disease and has major insurability implications. It is also a popular direct-to-consumer test. Calcification at various sites in the circulatory system including heart valves and arterial segments also has major underwriting implications. We will review all of these and highlight the RED FLAGS for insurability. 

 

Mild Cognitive Impairment (MCI) and Early Dementia 
There are several presentations of MCI, a precursor of dementia in most but not all cases. Distinguishing MCI from mild dementia is a critical determination because their mortality and morbidity prospects differ dramatically. This course will look at the risk factors, manifestations, diagnosis, management and prognosis in MCI contrasted to mild but irreversible dementia.

 

Premalignant/in situ Breast Tumors and BRCA 1+2
Recent insights have revealed that precancerous breast lesions and in situ carcinomas have more differences with prognostic and even direct mortality implications than we realized just a few years ago. We will review these disorders as well as the 2 most widely-used gene markers for breast cancer (and various other malignancies):  BRCA 1 and BRCA 2.

 

Lupus Erythematosus 2017
There have been many developments in our understanding of both systemic and cutaneous lupus since our 2010 course. Both BEST CASES and RED FLAG criteria have emerged. They will be featured along with the underwriting analysis of the ANA screening test (which is over-ordered in general practice)..

 

Rheumatoid, Osteo- and Other Forms of Arthritis
The various forms of arthritis differ substantially in their risk significance. New diagnostic tests and prognostic insights have emerged in RA while recent studies now raise significant issues about mortality in subsets of OA cases. We will also look at non-specific joint inflammation in terms of its influence on cardiovascular risk.

 

Personality Disorders, Eating Disorders and Obsessive Compulsive Disorder
These categories of psychiatric impairment are seldom addressed in insurance education despite their protean risk implications. This course will hone in on RED FLAGS and other factors in the more prevalent personality disorders, anorexia nervosa and the bulimic states and the whole obsessive compulsive disorder spectrum (where the mortality and morbidity risks are substantial yet often understated).

 

Depression 2017
There are many key aspects of depression that have changed in recent years including the subclinical depressive states, somatic symptoms, correlations with medical disorders, RED FLAGS for high risk cases and adjuvant Rx and other emerging therapies. These and other aspects of depression will be covered in this update covering the last decade.

 

Alcoholic and Nonalcoholic Fatty Liver Disease
There is a profound but sometimes illusive distinction between alcohol-related vs. other cases of hepatic steatosis. This course will elucidate these distinctions as well as the risk implications of NASH (nonalcoholic steatohepatitis), links between fatty liver and cardiovascular risk and high risk cases based on laboratory tests and novel alternatives to liver biopsy.